Florez Laboratory at Dana-Farber launches International Pregnancy and Lung Cancer Registry

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

For many women, a confirmation of pregnancy tends to evoke numerous emotions: excitement, shock, nervousness, joy, gratitude, and sometimes, even surprise. It is a moment dreamed, prayed, and planned for—but not for all.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Narjust Florez, MD
Associate director of the Cancer Care Equity Program, Thoracic medical oncologist, Dana-Farber Cancer Institute; Assistant professor of medicine, Harvard Medical School; Associate editor, JAMA Oncology
Lauren Keil
Senior research assistant, Florez Laboratory, Dana-Farber Cancer Institute
Rebekah Kaufman, MSc
Research assistant, Florez Laboratory, Dana-Farber Cancer Institute
Oyepeju Abioye-Akintola, MD, MSc
Research assistant, Florez Laboratory, Dana-Farber Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
Lauren Averett Byers, professor of thoracic/head & neck medical oncology at the University of Texas MD Anderson Cancer Center, received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology. The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer, which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.
Break Through Cancer has launched the PoweRD 2 Cure ALK+ Lung Cancer TeamLab, a collaboration among nine leading cancer research institutions, including Break Through Cancer’s five partner institutions: Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT’s Koch Institute for Integrative Cancer Research, and the University of Texas MD Anderson Cancer Center, as well as newly engaged collaborators from Mass General Brigham, Boston Children’s Hospital, the University of Colorado Cancer Center and Vanderbilt University Medical Center.
Narjust Florez, MD
Associate director of the Cancer Care Equity Program, Thoracic medical oncologist, Dana-Farber Cancer Institute; Assistant professor of medicine, Harvard Medical School; Associate editor, JAMA Oncology
Lauren Keil
Senior research assistant, Florez Laboratory, Dana-Farber Cancer Institute
Rebekah Kaufman, MSc
Research assistant, Florez Laboratory, Dana-Farber Cancer Institute
Oyepeju Abioye-Akintola, MD, MSc
Research assistant, Florez Laboratory, Dana-Farber Cancer Institute

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login